American CryoStem Corporation
CRYO
Other OTC0.00
USD
-0.04
- -
American CryoStem Corporation
CRYO
(Other OTC)
Recent
price
0.00
P/E
ratio
- -
div
yld
- -
ROIC.AI
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- Similar Companies
- Business
- American CryoStem Corporation (OTC: CRYO) develops, markets and licenses patented adipose tissue-based cellular technologies and proprietary services for regenerative and personalized medicine, with a focus on clinical processing, commercial bio-banking and therapeutic applications of autologous adipose-derived regenerative cells (ADRCs) and mesenchymal stem cells (ADSCs); core products and services include the CELLECT tissue harvesting, preservation and transportation system in 100mL and 250mL configurations containing proprietary media for optimal cell viability; ATGRAFT adipose tissue processing, cryopreservation and on-demand delivery for homologous use in cosmetic fat grafting, wound healing and multiple treatments from a single harvest; ATCELL autologous ADSC isolation, expansion and banking using patented ACSelerate animal-free cell culture media for research, clinical trials and potential therapies targeting post-concussion syndrome, Long COVID symptoms and musculoskeletal conditions; and Autokine-CM personalized topical skincare derived from patient-specific adipose cytokines and growth factors. The company operates an FDA-registered laboratory in Monmouth Junction, New Jersey, supporting a global network of licensed affiliates in locations including Hong Kong, China, Japan and Thailand, and serves physicians, researchers, cosmetic surgeons and clinical investigators with end-to-end solutions from tissue collection to point-of-care delivery. Founded in 2008 and headquartered in Eatontown, New Jersey, American CryoStem maintains ongoing clinical trials such as NCT05669261 for autologous MSCs in Long COVID treatment and NCT04744051 for post-concussion syndrome, while advancing its platform through institutional review board-approved protocols and collaborations without reported major acquisitions, funding rounds or strategic shifts in the last 1-2 years.
American CryoStem Executes LOI with Advanced Regenerative Associates to Conduct Wound Healing Clinical Study